Back to top
more

ResMed (RMD)

(Delayed Data from NYSE)

$272.60 USD

272.60
840,837

+1.41 (0.52%)

Updated Sep 16, 2025 03:59 PM ET

After-Market: $272.60 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 245)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why ResMed (RMD) is a Strong Growth Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Is it Worth Retaining ResMed Stock in Your Portfolio Now?

by Zacks Equity Research

RMD's Mask and Device sales fuel growth, but macro headwinds and fierce competition continue to challenge its performance.

Zacks Equity Research

Here's Why ResMed (RMD) is a Strong Growth Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Nyxoah Secures FDA Clearance for Genio System to Treat Sleep Apnea

by Zacks Equity Research

NYXH wins FDA approval for its leadless, battery-free Genio sleep apnea therapy, backed by strong trial results.

Zacks Equity Research

Why ResMed (RMD) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Why ResMed (RMD) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Here's How Much You'd Have If You Invested $1000 in ResMed a Decade Ago

by Zacks Equity Research

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Zacks Equity Research

Resmed Q4 Earnings & Revenues Beat Estimates, Stock Up, Margins Climb

by Zacks Equity Research

RMD tops Q4 earnings and revenue estimates with double-digit growth, rising margins and strong global device demand.

Zacks Equity Research

Here's What Key Metrics Tell Us About ResMed (RMD) Q4 Earnings

by Zacks Equity Research

The headline numbers for ResMed (RMD) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

ResMed (RMD) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

ResMed (RMD) delivered earnings and revenue surprises of +3.66% and +1.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Zacks Equity Research

Earnings Preview: Evolus, Inc. (EOLS) Q2 Earnings Expected to Decline

by Zacks Equity Research

Evolus (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Labcorp Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market

by Zacks Equity Research

LH tops Q2 estimates with double-digit EPS growth, margin gains and a raised 2025 outlook, lifting shares pre-market.

Zacks Equity Research

ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

ResMed (RMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

If You Invested $1000 in ResMed a Decade Ago, This is How Much It'd Be Worth Now

by Zacks Equity Research

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Zacks Equity Research

Boston Scientific Beats on Q2 Earnings, Raises 2025 View, Stock Up

by Zacks Equity Research

BSX beats Q2 estimates, raises full-year outlook as Cardiovascular sales surge and global revenues climb 22.8%.

Zacks Equity Research

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

ResMed Inc. (RMD) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

ResMed (RMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Quest Diagnostics Beats Q2 Earnings & Revenue Estimates, Stock Rises

by Zacks Equity Research

DGX tops Q2 estimates with 15.2% revenue growth and a strong EPS beat, lifting the stock 3.2% in pre-market trading.

Aparajita Dutta headshot

Buy These 5 Low-Leverage Stocks Amid Impressive Retail Sales Data

by Aparajita Dutta

With retail sales rebounding and Wall Street gaining, low-leverage stocks like NVS, RMD, WAB, ESLT and INGR offer scope for upside.

Zacks Equity Research

Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Akebia Therapeutics (AKBA) and ResMed (RMD) have performed compared to their sector so far this year.

Zacks Equity Research

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Zacks.com featured highlights Sprouts Farmers Market, Adobe, GE Aerospace and ResMed

by Zacks Equity Research

SFM, ADBE, GE, and RMD stand out as GARP stocks blending solid growth potential with reasonable valuations for smart returns.